Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2008

Henderson Ying C, Ahn Soon-Hyun, Kang Ya'an, Clayman Gary L

Abstract excerpt

PURPOSE: Papillary thyroid carcinomas (PTC) are the most common type of thyroid malignancy with one of the two mutations, RET/PTC rearrangement or BRAF mutation. Both mutations are able to activate the MEK/ERK signaling transduction pathway and result in the activation of transcription factors th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Carcinoma, Papillary
Share to Neoplasm Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins c-ret

Share to Pyridines

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 18676765
DOI: 10.1158/1078-0432.CCR-07-1772
PMCID: PMC4420193

Genes

RET
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18676765-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.PMID 18676765Read ↗

Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.Semantic proximity Read ↗

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.Semantic proximity Read ↗

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Selectively Targeting Mutant BRAF in Thyroid CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.